A "Bundle of Care" to Improve Anticoagulation Control in Patients Receiving Warfarin in Uganda and South Africa: Protocol for an Implementation Study.
Sub-Saharan Africa
anticoagulation control
drug monitoring
international normalized ratio
warfarin
warfarin bundle
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
19 Jul 2023
19 Jul 2023
Historique:
received:
23
02
2023
accepted:
30
05
2023
revised:
29
05
2023
medline:
19
7
2023
pubmed:
19
7
2023
entrez:
19
7
2023
Statut:
epublish
Résumé
The quality of warfarin anticoagulation among Sub-Saharan African patients is suboptimal. This is due to several factors, including a lack of standardized dosing algorithms, difficulty in providing timely international normalized ratio (INR) results, a lack of patient feedback on their experiences with treatment, a lack of education on adherence, and inadequate knowledge and training of health care workers. Low quality of warfarin anticoagulation, expressed as time in therapeutic range (TTR), is associated with higher adverse event rates, including bleeding and thrombosis, and ultimately, increased morbidity and mortality. Processes and interventions that improve this situation are urgently needed. This study aims to evaluate the implementation of the "warfarin bundle," a package of interventions to improve the quality of anticoagulation and thereby clinical outcomes. The primary outcome for this study is TTR over the initial 3 months of warfarin therapy. Patients aged 18 years or older who are newly initiated on warfarin for venous thromboembolism, atrial fibrillation, or valvular heart disease will be enrolled and followed up for 3 months at clinics in Cape Town, South Africa, and Kampala, Uganda, where the warfarin bundle is implemented. A retrospective review of the clinical records of patients on warfarin treatment before implementation (controls) will be used for comparison. This study uses a mixed methods approach of the implementation of patient- and process-centered activities to improve the quality of anticoagulation. Patient-centered activities include the use of clinical dosing algorithms, adherence support, and root cause analysis, whereas process-centered activities include point-of-care INR testing, staff training, and patient education and training. We will assess the impact of these interventions by comparing the TTR and safety outcomes across the 2 groups, as well as the cost-effectiveness and acceptability of the package. We started recruitment in June 2021 and stopped in August 2022, having recruited 167 participants. We obtained ethics approval from the University of Cape Town Faculty of Health Sciences Human Research Ethics Committee, the Provincial Health Research Committees in South Africa, the Joint Clinical Research Centre Institutional Review Board, Kampala, and the University of Liverpool Research Ethics Committee. As of February 2023, data cleaning and formal analysis are underway. We expect to publish the full results by December 2023. We anticipate that the "bundle of care," which includes a clinical algorithm to guide individualized dosing of warfarin, will improve INR control and TTR of patients in Uganda and South Africa. We will use these findings to design a larger, multisite clinical trial across several Sub-Saharan African countries. DERR1-10.2196/46710.
Sections du résumé
BACKGROUND
BACKGROUND
The quality of warfarin anticoagulation among Sub-Saharan African patients is suboptimal. This is due to several factors, including a lack of standardized dosing algorithms, difficulty in providing timely international normalized ratio (INR) results, a lack of patient feedback on their experiences with treatment, a lack of education on adherence, and inadequate knowledge and training of health care workers. Low quality of warfarin anticoagulation, expressed as time in therapeutic range (TTR), is associated with higher adverse event rates, including bleeding and thrombosis, and ultimately, increased morbidity and mortality. Processes and interventions that improve this situation are urgently needed.
OBJECTIVE
OBJECTIVE
This study aims to evaluate the implementation of the "warfarin bundle," a package of interventions to improve the quality of anticoagulation and thereby clinical outcomes. The primary outcome for this study is TTR over the initial 3 months of warfarin therapy.
METHODS
METHODS
Patients aged 18 years or older who are newly initiated on warfarin for venous thromboembolism, atrial fibrillation, or valvular heart disease will be enrolled and followed up for 3 months at clinics in Cape Town, South Africa, and Kampala, Uganda, where the warfarin bundle is implemented. A retrospective review of the clinical records of patients on warfarin treatment before implementation (controls) will be used for comparison. This study uses a mixed methods approach of the implementation of patient- and process-centered activities to improve the quality of anticoagulation. Patient-centered activities include the use of clinical dosing algorithms, adherence support, and root cause analysis, whereas process-centered activities include point-of-care INR testing, staff training, and patient education and training. We will assess the impact of these interventions by comparing the TTR and safety outcomes across the 2 groups, as well as the cost-effectiveness and acceptability of the package.
RESULTS
RESULTS
We started recruitment in June 2021 and stopped in August 2022, having recruited 167 participants. We obtained ethics approval from the University of Cape Town Faculty of Health Sciences Human Research Ethics Committee, the Provincial Health Research Committees in South Africa, the Joint Clinical Research Centre Institutional Review Board, Kampala, and the University of Liverpool Research Ethics Committee. As of February 2023, data cleaning and formal analysis are underway. We expect to publish the full results by December 2023.
CONCLUSIONS
CONCLUSIONS
We anticipate that the "bundle of care," which includes a clinical algorithm to guide individualized dosing of warfarin, will improve INR control and TTR of patients in Uganda and South Africa. We will use these findings to design a larger, multisite clinical trial across several Sub-Saharan African countries.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
DERR1-10.2196/46710.
Identifiants
pubmed: 37467034
pii: v12i1e46710
doi: 10.2196/46710
pmc: PMC10398551
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e46710Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
©Andrea L Jorgensen, Catherine Orrell, Catriona Waitt, Cheng-Hock Toh, Christine Sekaggya-Wiltshire, Dyfrig A Hughes, Elizabeth Allen, Emmy Okello, Gayle Tatz, Giovanna Culeddu, Innocent G Asiimwe, Jerome Roy Semakula, Johannes P Mouton, Karen Cohen, Marc Blockman, Mohammed Lamorde, Munir Pirmohamed. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 19.07.2023.
Références
PLoS One. 2020 Jan 29;15(1):e0227458
pubmed: 31995565
Br J Clin Pharmacol. 2021 Oct;87(10):3699-3705
pubmed: 33624331
Br J Clin Pharmacol. 2021 Aug;87(8):3056-3068
pubmed: 33586223
Popul Health Metr. 2003 Dec 16;1(1):11
pubmed: 14678566
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Thromb Haemost. 1993 Mar 1;69(3):236-9
pubmed: 8470047
Circ Cardiovasc Qual Outcomes. 2011 Jul;4(4):416-24
pubmed: 21712521
PLoS One. 2017 Nov 20;12(11):e0188482
pubmed: 29155884
PLoS One. 2011;6(12):e28096
pubmed: 22194808
Jt Comm J Qual Patient Saf. 2017 Jun;43(6):299-307
pubmed: 28528624
N Engl J Med. 2009 Feb 19;360(8):753-64
pubmed: 19228618
Patient Saf Surg. 2016 Sep 21;10:20
pubmed: 27688807
Clin Pharmacol Ther. 2021 Jun;109(6):1564-1574
pubmed: 33280090
Clin Pharmacol Ther. 2008 Sep;84(3):326-31
pubmed: 18305455